Perfil hepático e eletrolítico de cães idosos sadios ou com doença renal crônica tratados com o antioxidante n-acetilcisteína

Abstract

N-acetylcysteine (NAC) has been used in hepatic and renal protection in experimental models. The objective of this study was to evaluate the effects of NAC treatment on profile hepatic and electrolytic for older dogs healthy or with chronic kidney disease (CKD) naturally acquired and clinically stable. Four groups of aged dogs (9 - 15 years) were evaluated, including the control normal group (N-C, n = 4), normal group treated (N-T, n = 5), group control chronic kidney disease (CKD-C, n = 5) and the group treated chronic kidney disease (CKD-T, n = 4). The groups N-T and CKD-T were submitted to treatment with NAC (VO) at the dose of 10 mg/kg bid for 60 days. The groups N-C and CKD-C were not submitted to any type of treatment. The serum concentration total protein (SPt), albumin (SAlb), alanina amino-transferase (SALT), alkaline phosphatase (SFA), sodium (SNa), potassium (SK), phosphorus (SP), total calcium (SCat) and the calcium ionc (SCai) were previously evaluated, 15, 30, 45 and 60 days after being treated with NAC. The data were compared by ANOVA for repeated measures followed by the Tukey test (α=0,05). The NAC had no effect on the hepatic profile of the dogs studied. The SNa in the N-T (149 ± 4,99 mg/dL) was higher compared to N-C (141 ± 1,32 mg/dL) (P<0,05). In multiple comparisons of mean SK and SCat in the N-T average at 15 days of treatment (4,94 ± 0,38 mEq/L; 12,37 ± 0,45 mEq/L) was higher than the average baseline (4,26 ± 0,22 mEq/L; 10,13 ± 0,56 mEq/L). It was conclude that the antioxidant NAC promoted in older dogs healthy, increase of SK and SCat.